Production (Stage)
CG Oncology, Inc.
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -90.17% | 45,500.00% | 377.78% | 14.43% | 172.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -90.17% | 45,500.00% | 377.78% | 14.43% | 172.68% |
| Cost of Revenue | 59.60% | 64.01% | 99.57% | 108.97% | 119.46% |
| Gross Profit | -64.35% | -61.23% | -99.14% | -110.02% | -118.11% |
| SG&A Expenses | 155.51% | 288.10% | 249.48% | 228.11% | 179.21% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 83.74% | 98.93% | 129.90% | 133.44% | 131.95% |
| Operating Income | -87.83% | -96.58% | -129.56% | -134.48% | -131.14% |
| Income Before Tax | -103.45% | -92.07% | -75.71% | -86.37% | -95.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -103.45% | -92.07% | -75.71% | -86.37% | -95.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -103.45% | -92.07% | -75.71% | -86.37% | -95.38% |
| EBIT | -87.83% | -96.58% | -129.56% | -134.48% | -131.14% |
| EBITDA | -87.76% | -96.63% | -129.46% | -134.51% | -131.19% |
| EPS Basic | -25.68% | 89.43% | 92.26% | 92.07% | 88.81% |
| Normalized Basic EPS | -25.66% | 85.64% | 89.75% | 89.13% | 83.99% |
| EPS Diluted | -25.68% | 89.43% | 92.26% | 92.07% | 88.81% |
| Normalized Diluted EPS | -25.66% | 85.64% | 89.75% | 89.13% | 83.99% |
| Average Basic Shares Outstanding | 61.88% | 1,237.29% | 1,613.51% | 1,615.25% | 1,120.75% |
| Average Diluted Shares Outstanding | 61.88% | 1,237.29% | 1,613.51% | 1,615.25% | 1,120.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |